Answers are grounded in this paper and cite their sources.
Background: Fibrin-specific lytic agents like tenecteplase (TNK) have improved the patency rates substantially. Real-world postmarketing safety and efficacy evaluation hold lot of importance. Objectives: The present study was a prospective, multicenter, phase IV study to evaluate postmarketing safety and efficacy of TenecteRel ® (TNK). Methods: The present study was a postmarketing multicenter, phase IV study to evaluate postmarketing safety and efficacy of TenecteRel ® . Two hundred and two patients of STEMI presenting within 6 h of onset of symptoms, were included in the study. A single dose of tenecte was administered and patients were followed up till day 30. Safety evaluation included adverse events monitoring, physical examination, vital signs, and immunogenicity assessment. Efficacy assessment was based on mortality and nonfatal stroke at 30 days and rates of bleeding events and nonfatal inhospital cardiac events. Results: A total of 69 treatment-emergent adverse events (TEAEs) were reported. There were 42 (20.79%) patients who had at least one TEAE and 9 (4.46%) patients with TEAE related to study medication. Most commonly reported (≥5%) TEAEs were related to gastrointestinal disorders 17 (8.42%) and general disorders and administration site conditions 13 (6.93%). One hundred and ninety-four (96.04%) patients had the net clinical benefit (defined as the absence of mortality and nonfatal stroke at day 30). No patient had an incidence of stroke. Bleeding events were 3 (1.49%) all of which were nonserious and minor in nature. Conclusions: The present phase IV study confirms that TenecteRel ® of Reliance Life Sciences is well tolerated and the safety and efficacy profile is comparable to the innovator product data.
No takes yet. Share an insight, caveat, or question.
Apsangikar et al. (2023) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: